The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...

Vigil Neuroscience said the Food and Drug Administration removed a partial clinical hold on its ongoing Phase 1 clinical trial of a treatment for Alzheimer's disease, VG-3927. The clinical-stage ...

But the healthcare system in the US still struggles to provide adequate care for those with serious mental illness ...

The new Alzheimer’s drug Kinsula is offering hope for patients by slowing down the progression of the disease. Neurologist Dr. Mauricio Concha administered the drug ...

Researchers at UCLA Health have discovered a molecule that shows promise in restoring memory and cognitive function in mice ...

For Lennart Mucke, MD, founding director of the Gladstone Institute of Neurological Disease, these new drugs mark an ...

Leqembi, an Alzheimer's drug from Biogen and Eisai, faces hurdles with respect to reimbursement and diagnostic uncertainties, diagnostic test requirements and the need for regular brain scans, CNBC ...

THURSDAY, Sept. 11, 2024 (HealthDay News) -- Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab ...

The FDA and manufacturers routinely allow doctors and hospitals to continue using medical devices that could cause serious harm or death.

Kearney physician Dr. Bradley Rodgers will soon offer Kisunla, the first drug proven to slow the early onset of Alzheimer’s.

As Gladstone Institutes commemorates World Alzheimer’s Month, Lennart Mucke, MD, discusses what’s next for Alzheimer’s ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...